G1 Therapeutics Raises $94 Million in Equity Financing
Pharmaceutical giants Pfizer and Novartis were first to gain regulatory approval with drugs that block a pair of enzymes important to tumor growth in breast cancer. Clinical-stage biotech G1 Therapeutics has a different approach to those same enzymes and will ask investors in the public markets to get on board. Research Triangle Park, NC-based G1 has filed for an initial public offering that could raise up to $115 million. G1 has yet to work out the number of shares it will offer and at what price. It has applied for a stock listing on the Nasdaq exchange under the stock symbol “GTHX.”
Modified on August 10, 2017